Cerebral vasodilator therapy in stroke.
D000433:1-Propanol / Q000627:therapeutic use; D000086:Acetazolamide / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D001794:Blood Pressure; D002245:Carbon Dioxide / Q000097:blood; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D003510:Cyclohexanes / Q000627:therapeutic use; D004877:Ergoloid Mesylates / Q000627:therapeutic use; D005029:Ethylenediamines / Q000627:therapeutic use; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use; D009756:Nylidrin / Q000627:therapeutic use; D010101:Oxygen Consumption; D010208:Papaverine / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014978:Xenon
D001565:Benzoates; D003510:Cyclohexanes; D005029:Ethylenediamines; D008333:Mandelic Acids; D014665:Vasodilator Agents; D002245:Carbon Dioxide; D014978:Xenon; D009756:Nylidrin; D004877:Ergoloid Mesylates; D000433:1-Propanol; D010208:Papaverine; D000086:Acetazolamide